Eliminating the finger-stick necessary to monitor blood glucose levels for diabetics would be a significant med tech industry accomplishment. Even the biggest corporate players are taking the challenge seriously--as witnessed by the Google partnership with Novartis last month to develop glucose monitoring contact lenses.
Back in April, Merck rolled out its America's Diabetes Challenge: Get to Your Goals campaign, aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck has a new-but-similar campaign launching, but with a tighter focus: the Hispanic community, which is disproportionately affected by the disease.
Researchers say they successfully tested in mice a molecular implant that contains gene-based mechanisms for delivering insulin based on feedback from an associated pH biosensor. By maintaining a healthy pH level between 7.35 and 7.45, the therapy, consisting of different genes and proteins, would prevent potentially fatal metabolic shock (ketoacidosis) in diabetics.
Becton, Dickinson and Company today announced that its BD AutoShield Duo pen for the delivery of insulin and diabetes drugs is now available in retail pharmacies.
Just because a drug is third to market doesn't mean it's not a viable player--especially if it has safety on its side. Just ask Biogen Idec, whose Tecfidera has quickly eclipsed its predecessors to take the multiple sclerosis market by storm. But is that type of launch in the cards for Eli Lilly and Boehringer Ingelheim's diabetes med Jardiance?
Mannkind endured a grueling 10-year battle for FDA approval of its inhaled insulin drug/device combination product, Afrezza. Now the dillema is how to sell it. The company needs to find a marketing partner fast.
This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
Researchers at Boston University and Massachusetts General Hospital found patients with Type 1 diabetes who used an artificial pancreas synced wirelessly to an iPhone were more likely to have a normal range of blood glucose levels and fewer dangerous lows and highs.
The emergence of electronic health records has made it possible to build a more complete picture of the health of populations. To realize this vision for diabetes patients, AstraZeneca has signed up to sponsor a registry that gathers data from primary care physicians and specialists in other fields.
Senseonics has raised a $20 million venture round to get its implantable blood glucose monitor for diabetics through pivotal trials.